NCT05367232View on ClinicalTrials.gov

A Study of ICP-033 in Patients With Advanced Solid Tumors

PHASE1RecruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

February 25, 2022

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2025

Conditions
Patients With Advanced Solid Tumors
Interventions
DRUG

ICP-033 tablet

Administered orally, once a day, 28 days per cycle

Trial Locations (1)

610041

RECRUITING

West China Hospital of Sichuan University, Sichuan

All Listed Sponsors
lead

Beijing InnoCare Pharma Tech Co., Ltd.

INDUSTRY